Clinical trials: Chemotherapy-Related Toxicities
Anemia, Breast Cancer
Epoetin Alfa in Treating Anemia in Patients Who Are Receiving Chemotherapy
RATIONALE: Epoetin alfa may stimulate red blood cell production and treat anemia in patients with cancer who are receiving chemotherapy.
- Conditions
- Anemia, Breast Cancer, Chronic Myeloproliferative Disorders, Drug/Agent Toxicity by Tissue/Organ
- Trial name
- NCT00003600
- Testing
- epoetin alfa
- Where
- 21 sites in United States, Canada
- Volunteers
- 344 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Oral Mucositis, Chemotherapy-induced Oral Mucositis
Ozone Therapy With Biomimetic Oral Care for Cancer-Related Oral Mucositis
Oral mucositis is a frequent and often debilitating complication of radiotherapy and chemotherapy, particularly in patients treated for head and neck cancers.
- Conditions
- Oral Mucositis, Chemotherapy-induced Oral Mucositis, Head and Neck Neoplasms
- Trial name
- OZOMUC (NCT07491536)
- Testing
- Gas Ozone Therapy, Biomimetic Oral Care Regimen
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Pavia
Oral Mucositis
Ozone Therapy for Cancer Therapy-Related Oral Mucositis
This retrospective observational study will evaluate clinical data already available from adult cancer patients who developed cancer therapy-related oral mucositis during radiotherapy and/or chemotherapy and who were managed in…
- Trial name
- OMUC-O3 (NCT07638904)
- Testing
- Combined Ozone-Based Oral Care Protocol
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- University of Pavia
Solid Tumor, Capecitabine
Association of Genetic Polymorphisms With Capecitabine-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
Capecitabine is one of the most active agents in the treatment of many kinds of solid tumors. However, variability in toxicity and response remains a major problem for patients receiving capecitabine.
- Conditions
- Solid Tumor, Capecitabine, Drug-Related Side Effects and Adverse Reactions, Pharmacogenetics
- Trial name
- NCT03258099
- Testing
- detection of genotype
- Where
- 7 sites in China
- Volunteers
- 2,200 people
- Sponsor
- Cui Yimin
Drug/Agent Toxicity by Tissue/Organ, Lung Cancer
Amifostine to Prevent Side Effects in Patients Who Are Receiving Chemotherapy and Radiation Therapy for Limited-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Drugs such as amifostine may protect normal cells from the side effects of chemotherapy and radiation…
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Lung Cancer, Radiation Toxicity
- Trial name
- NCT00003583
- Testing
- amifostine trihydrate, cisplatin, etoposide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Florida
Cardiotoxicity Induced by Drug Therapy for Breast Cancer
The Use of Shengmai San to Prevent Anthracycline Sequential Trastuzumab Therapy Related Cardiac Toxicity
To evaluate the effectiveness and safety of Shengmai San in preventing anthracycline sequential trastuzumab therapy related cardiac toxicity through a prospective randomized controlled study.
- Trial name
- START (NCT06214195)
- Testing
- Shengmai San (ingredients include ginseng, Ophiopogon japonicus, and Schisandra chinensis)
- Where
- China
- Volunteers
- 276 people
- Sponsor
- Zhejiang Cancer Hospital
Cancer Therapy-related Cardiovascular Toxicity
Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics
The purpose of this study was to explore the relationship between early myocardial injury caused by tumor drug therapy and intestinal microbial structure changes by echocardiographic two-dimensional speckle tracking technique and…
- Trial name
- NCT05730777
- Testing
- Bifidobacterium Bifidum Oral Capsule, Cisplatin, Carboplatin
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Peking University Third Hospital
Gestational Trophoblastic Tumor, Effects of Chemotherapy
Combination of Methotrexate(MTX) and Actinomycin(ACTD) in the Low Risk Gestational Trophoblastic Neoplasma （GTN） Patients With Score of 5-6
In this study, a prospective, multicenter randomized controlled study was conducted to compare the clinical efficacy and toxicity response of combination MTX+ACTD multi-course regimen in low-risk GTN patients with score 5-6 with…
- Conditions
- Gestational Trophoblastic Tumor, Effects of Chemotherapy, Drug Toxicity
- Trial name
- NCT03885388
- Testing
- MTX, MTX+ACTD
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Women's Hospital School Of Medicine Zhejiang University
Solid Carcinoma, 5-Fluorouracil Toxicity
Prevention of Chest Pain in Chemo-treated Cancer Patients
This is a prospective, exploratory, randomised clinical trial. Patients with diagnosed cancer that are to be treated with 5-fluorouracil (5-FU) will be randomised into standard oncological treatment or a cardiological assessment…
- Conditions
- Solid Carcinoma, 5-Fluorouracil Toxicity, Cardiotoxicity, Chemotherapeutic Toxicity
- Trial name
- CATCH (NCT03486340)
- Testing
- Cardiologic assessment
- Where
- Denmark
- Volunteers
- 218 people
- Sponsor
- Vejle Hospital
Leukemia, Lymphoma
Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs such as amifostine may protect normal cells from the side effects of chemotherapy.
- Conditions
- Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003294
- Testing
- filgrastim, amifostine trihydrate, carboplatin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Roswell Park Cancer Institute
Osteosarcoma, Survival
Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma
Treatment strategies for high-grade osteosarcoma with multidrug chemotherapy and resection result in 3-year event-free survival of 60-70%.
- Conditions
- Osteosarcoma, Survival, Chemotherapy Effect, Toxicity, Drug
- Trial name
- MAPAC (NCT04351308)
- Testing
- MAPI chemotherapy, Apatinib Mesylate, Camrelizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University People's Hospital
Cancer, Cancer-related Problem/Condition
Cancer and Aging Research Group (CARG) Chemotherapy Toxicity Risk Scores in Older Adults With Cancer in China
The goal of this observational study is to learn about the impact of chemotherapy-related toxicity on older cancer patients in China.
- Trial name
- NCT06717178
- Testing
- Chemotherapy
- Where
- 2 sites in China
- Volunteers
- 360 people
- Sponsor
- RenJi Hospital
Cardiac Toxicity, Sarcoma
Combination Chemotherapy Plus Dexrazoxane in Treating Patients With Newly Diagnosed Nonmetastatic Osteosarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003937
- Testing
- cisplatin, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- 148 sites in United States, Australia and 4 more
- Volunteers
- 253 people
- Sponsor
- Children's Oncology Group
Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer
Chemotherapy Plus Radiation Therapy With or Without Amifostine in Treating Patients With Locally Advanced Cancer of the Nasopharynx
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Head and Neck Cancer, Oral Complications, Radiation Toxicity
- Trial name
- NCT00025298
- Testing
- amifostine trihydrate, carboplatin, cisplatin
- Where
- 13 sites in Belgium, France and 4 more
- Volunteers
- 5 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Drug/Agent Toxicity by Tissue/Organ, Leukemia
Amifostine and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003268
- Testing
- amifostine trihydrate, cytarabine, idarubicin
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Lymphoma
Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- ManteauRiBVD (NCT00740415)
- Testing
- rituximab, bortezomib, dexamethasone
- Where
- France
- Volunteers
- 39 people
- Sponsor
- French Innovative Leukemia Organisation
Breast Cancer, Cardiac Toxicity
Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Nonmetastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, fluorouracil, epirubicin hydrochloride, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Conditions
- Breast Cancer, Cardiac Toxicity, Perioperative/Postoperative Complications
- Trial name
- NCT01093235
- Testing
- bevacizumab, cyclophosphamide, docetaxel
- Where
- United Kingdom
- Volunteers
- 800 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Predicting Chemotherapy Related Toxicity in Elderly Patients
G8, VES-13 and CARG Scores in Predicting Chemotherapy Toxicity in Geriatric Cancer Patients
All participants' medical information will be collected for use as a baseline, including tumor-specific variables, nutritional status, functional status, psychological status, cognitive function, social support, and…
- Trial name
- NCT04992455
- Testing
- Older Patients Receiving Chemotherapy
- Where
- Turkey (Türkiye)
- Volunteers
- 150 people
- Sponsor
- Namik Kemal University
Breast Cancer, Drug/Agent Toxicity by Tissue/Organ
Combination Chemotherapy After Surgery With or Without Chinese Herbal Therapy to Treat Symptoms in Women With Breast Cancer
RATIONALE: Herbs used in traditional Chinese medicine may decrease the side effects of chemotherapy. PURPOSE: Randomized phase I/II trial to study the effectiveness of herbs used in traditional Chinese medicine in decreasing the…
- Trial name
- NCT00028964
- Testing
- Chinese herbs, cyclophosphamide, doxorubicin hydrochloride
- Where
- United States
- Sponsor
- University of California, San Francisco
Cardiac Toxicity, Unspecified Childhood Solid Tumor, Protocol Specific
Oblimersen Plus Combination Chemotherapy and Dexrazoxane in Treating Children and Adolescents With Relapsed or Refractory Solid Tumors
Phase I trial to study the effectiveness of oblimersen plus combination chemotherapy and dexrazoxane in treating children and adolescents who have relapsed or refractory solid tumors.
- Trial name
- NCT00039481
- Testing
- oblimersen sodium, dexrazoxane hydrochloride, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Cancer Institute (NCI)